Our top pick for
Oncorus, Inc is a biotechnology business based in the US. Oncorus shares (ONCR) are listed on the NASDAQ and all prices are listed in US Dollars. Oncorus employs 51 staff and has a market cap (total outstanding shares value) of USD$430.6 million.
|52-week range||USD$14.6 - USD$37.8603|
|50-day moving average||USD$25.2588|
|200-day moving average||USD$23.8925|
|Wall St. target price||USD$38.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$430.6 million|
TTM: trailing 12 months
There are currently 316,383 Oncorus shares held short by investors – that's known as Oncorus's "short interest". This figure is 6.1% down from 336,803 last month.
There are a few different ways that this level of interest in shorting Oncorus shares can be evaluated.
Oncorus's "short interest ratio" (SIR) is the quantity of Oncorus shares currently shorted divided by the average quantity of Oncorus shares traded daily (recently around 68333.261339093). Oncorus's SIR currently stands at 4.63. In other words for every 100,000 Oncorus shares traded daily on the market, roughly 4630 shares are currently held short.
To gain some more context, you can compare Oncorus's short interest ratio against those of similar companies.
However Oncorus's short interest can also be evaluated against the total number of Oncorus shares, or, against the total number of tradable Oncorus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oncorus's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Oncorus shares in existence, roughly 10 shares are currently held short) or 0.0212% of the tradable shares (for every 100,000 tradable Oncorus shares, roughly 21 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oncorus.
Find out more about how you can short Oncorus stock.
We're not expecting Oncorus to pay a dividend over the next 12 months.
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.